Table 3 Univariate Cox regression analysis for OS in subjects who received ASCT (n = 123)
Variable | Categories | HR (95% CI) | P value | Log-rank |
|---|---|---|---|---|
Sex | Male | 1.31 (0.60–2.84) | 0.503 | 0.501 |
Age | < 53 | 1.00 | 0.464 | |
53–60 | 1.61 (0.63–4.09) | 0.317 | ||
≥ 60 | 0.99 (0.35–2.81) | 0.978 | ||
Age, continuous | Per 1 year | 1.02 (0.97–1.08) | 0.397 | |
Chemotherapy regimen | VTD | 1.00 | 0.048 | |
VMP | 5.79 (1.23–27.29) | 0.026 | ||
Other 3-drugs* | 2.74 (1.06–7.12) | 0.038 | ||
Miscellaneous | 2.10 (0.76–5.79) | 0.154 | ||
Radiotherapy | Yes | 1.66 (0.67–4.14) | 0.277 | 0.272 |
R-ISS stage | I | 1.00 | 0.001 | |
II | 2.92 (1.04–8.22) | 0.042 | ||
III | 6.86 (2.23–21.10) | < 0.001 | ||
Hypercalcemia | Yes | 0.64 (0.19–2.19) | 0.460 | 0.456 |
Renal insufficiency | Yes | 1.19 (0.48–2.96) | 0.715 | 0.715 |
Anemia | Yes | 1.36 (0.65–2.97) | 0.437 | 0.435 |
Bone lesions positive | Yes | 0.60 (0.21–1.75) | 0.350 | 0.345 |
Extramedullary disease | Yes | 0.80 (0.24–2.66) | 0.712 | 0.711 |
FDG parameter | ||||
- SUVmax | High | 0.69 (0.32–1.49) | 0.342 | 0.339 |
- SUVmax, continuous | Per 1 g/ml | 1.06 (0.99–1.13) | 0.110 | |
- SUVmean | High | 0.68 (0.31–1.54) | 0.357 | 0.354 |
- SUVmean, continuous | Per 1 g/ml | 0.69 (0.35–1.36) | 0.289 | |
- MTV | High | 1.80 (0.83–3.90) | 0.138 | 0.132 |
- MTV, continuous | Per 1 cm 3 | 1.00 (1.00–1.00) | 0.009 | |
- TLG | High | 1.61 (0.74–3.51) | 0.234 | 0.229 |
- TLG, continuous | Per 1 | 1.00 (1.00–1.00) | 0.021 | |
- FL | > 3 | 1.19 (0.54–2.62) | 0.674 | 0.674 |